Shingles Vaccine to be Offered to Those Turning 60 in 2027
Starting in 2027, individuals turning 60 will be offered a shingles vaccination, according to a recent announcement. The decision comes after advice from the Netherlands’ National Institute for Public Health and the Environment (RIVM) to maximize the impact of available funding.
Currently, those already 60 or older will not be eligible for the free vaccination program, as extending it to this larger group would be too costly. The cost of the two-dose vaccine is approximately €400 per person. However, individuals who do not qualify for the program can still receive the vaccine privately, but will be responsible for the full cost.
The government plans to invest a minimum of €47 million annually starting in 2027, increasing to €53 million per year from 2030, with funding continuing through 2039. This funding is expected to allow for the vaccination of at least 150,000 people each year.
Shingles, caused by the same virus as chickenpox, manifests as a painful, itchy rash. The vaccine is particularly beneficial for older adults, who are more susceptible to the condition and its complications. The choice of age 60 was determined to be the most cost-effective approach to prevent the majority of shingles cases.
Two vaccines are available against shingles: Shingrix and Zostavax. The RIVM recommends Shingrix, as it prevents nine out of ten cases of shingles and associated long-term pain, and offers lasting protection. The Shingrix vaccine requires two doses, administered between two and six months apart. More information about the shingles vaccination is available from the RIVM.
Research suggests the Shingrix vaccine is highly effective, preventing around 90% of shingles cases in adults aged 50 and older, and reducing the risk of long-term pain by the same amount. Even six to ten years after vaccination, protection remains above 80%. This high level of efficacy underscores the importance of vaccination for preventing this debilitating condition.
The decision to focus on those turning 60 reflects a pragmatic approach to public health resource allocation. While acknowledging the financial burden for those over 60 who wish to be vaccinated, officials maintain that this strategy allows for the most effective use of available funds. The announcement has sparked debate about equitable access to preventative healthcare.
